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INTRODUCTION
Angioimmunoblastic T-cell lymphoma (AITL) is one of the most frequent nodal T-cell lym-
phoma.1,2 It derives from follicular helper T-cell (TFH).3 It accounts for 15 - 20% of all peripheral 
T-cell lymphomas and usually affects patients in the seventh decade of life.1,2,4,5 AITL’s incidence 
is nearly 0,05 new patient case per 100,000 people in US, and there’s no sex predilection.6,7
It is characterized by polymorphic lymph node infiltrate with a prominent proliferation of high 
endothelial venules and follicular dendritic cells, different immune disorders and a poor progno-
sis.8,9 The neoplastic T-cells express CD2, CD3, CD4 and CD10 but the marker’s specificity has 
been debated. More specific indicators of AITL are CXCL-13, programmed death-1 (PD1), in-
ducible costimulator (ICOS), and BCL6 transcription factor.10-12 Nearly all patients have EBV-in-
fected B cells in their lymph nodes, but the presence of these EBV-positive cells doesn’t correlate 
with survival.13-15 However, the role of EBV isn’t clear yet: it could be secondary to the immune 
deregulation, or it could be a fundamental factor involved in disease’s start and progression. 
AITL is frequently associated with polyclonal B-cell or plasma cell proliferation;8 this neoplastic 
proliferation of B-cells on parallel with AITL could be motivated by a cluster of pluripotent cells 
with the ability to differentiate into B-cells and T-cells neoplasm simultaneously, maybe due to 
exposition to pharmacological therapies or specific mutagens.
Clinical manifestations are often represented by group-B symptoms (fever, night sweats, weight 
loss), hepatosplenomegaly, anemia, lymphadenopathy, polyclonal hypergammaglobulinemia, 
thrombocytopenia and/or a large variety of immune disorders.16,17 Up to 50% of develop cutane-
ous lesions, expression of extranodal diffusion of the tumor: urticaria, purpura, pruritic maculo-
papular eruptions, erosions, plaques, nodules, petechiae.18-20 Despite occasionally spontaneous 
remissions,21 AITL prognosis is poor, with a median overall survival of 3 years.
THERAPEUTIC OPTIONS
The first line of treatment is currently focused on anthracycline-based regimens: ACVBP (dose-
intense Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone), CHOP (Cyclo-
phosphamide, Doxorubicin, Vincristine, Prednisone) or mBACOD (Methotrexate, Bleomycin, 
Doxorubicin, Cyclophosphamide, Vincristine, Dexamethasone). However, there is no difference 
in overall survival when comparing ACVBP, CHOP and mBACOD. Other substances could 
be added to this three “standard regimens” to improve survival of the patients: Thalidomide, 
Pralatrexate, Romidepsin, Belinostat, Rituximab, Alemtuzumab, Bevacizumab, Bortezomib, Za-
nolimumab. The real impact of this substances isn’t entirely clear, for this reason, they aren’t 
included in standard guidelines. However, the effects of any therapy are mostly short term and 
associated with early relapse.
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CASE PRESENTATION
A 74-year-old man was evaluated for persistent and severe chest 
pain in the substernal region developed from two months. Dur-
ing the last two weeks, the pain also appeared at the left hip 
and was associated with a quickly and progressive loss of the 
strength of the lower limbs. At the time of the evaluation, the 
patient showed lower extremity para-paresis, loss of sensation 
below to T7 and disappearance of left hip pain. Abdominal and 
thoracic CT showed a large right para-vertebral lesion extending 
from T2 to L2 (35×10×5 cm) with infiltration of V-VI-VII ri-
ght ribs, right pleura, right vertebral pedicles-laminas transverse 
processes from T3 to T7 (Figures 1, 2, 3 and 4). The lesion pen-
etrated into the vertebral foramen compressing the spinal cord 
from T5 to T6. Other three solid lesions were detected on the 
sternum body (3.4×2.7×2  cm), on the left para-vertebral mus-
cles from L3 to S1 (5×4.3×9.7 cm) with contralateral extension, 
and on the left iliac crest (7×7×10 cm). The infiltration of the 
lesions determined pathological fractures of the VI rib and iliac 
crest. An echographic-guided FNAB of the right paravertebral 
lesion was made. The sample was composed of medium and 
small-sized lymphoid elements with poor basophil cytoplasm, 
central and prominent nucleoli. IHC revealed positivity for CD3 
and CD4, and negativity for CD8, CD20, CD30, CD99. Large 
immunoblastic cells with positivity for CD138 (plasma B-cells 
marker) and MUM-1 (immunoblast marker) were also identi-
fied, these elements didn’t show immunoglobulin light chain 
clonal restriction. Proliferation index Ki67 was 90%. There were 
consistent vascular proliferation and necrosis areas. On the basis 
of these elements, the Angioimmunoblastic T-Cell Lymphoma 
was diagnosed.
THERAPY Surgical stabilization or the verterbral column and 
tumor resection were impracticable because the extension and 
the size of the neoplasm and the massive infiltration into adja-
cent tissues, thus the only possible treatment was the chemother-
apy (Figures 5 and 6). Given the poor condition of the patient, an 
aggressive chemotherapy was not possible, therefore the chosen 
regimen was the CHOEP regimen (Cyclophosphamide, Doxoru-
bicin, Vincristine, Etoposide, Methylprednisolone). The first two 
courses of the treatment were well tolerated form hematological 
point of view and the patient did not show significant cytopeni-
as. However, the neurological situation didn’t improve: parapa-
resis and loss of sensibility remained unchanged. After the third 
course of chemotherapy, the patient underwent the usual control 
CT that showed a significant worsening of the disease: the para-
vertebral lesions increased of size and the spinal cord compres-
sion extended from T5 to T7 and a large right pleural effusion 
was detected (Figures 7 and 8). At this point, the chemotherapy 
was interrupted, and the patient underwent only palliative care. 
Few days later the patient died of septic shock.
Figure 1: Hematoxylin and eosin-stained biopsy sample. Figure 2: Diffuse positivity for CD3 (T-cell marker).
Figure 3: Diffuse positivity for CD4 (T-cell marker). Figure 4: Proliferation index Ki67.
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Figure 7: Positivity for CD138 (Plasma B-cells 
marker). 
Figure 5: Negativity for CD8 (T-cell marker). Figure 6: Negativity for CD20 (B-cell marker).
Figure 8: Positivity for MUM-1 (Immunoblast 
marker).
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